Emerging hepatotoxicity biomarkers and their potential to improve understanding and management of drug-induced liver injury.
Biomarkers of drug-induced liver injury (DILI) are essential for the diagnosis of severe cases of DILI in clinical trials and clinical practice, but the currently used biomarker paradigm detects damage after it has occurred and has limited prognostic value. The development of new biomarker strategies that improve the diagnosis of DILI by providing increased specificity and/or by identifying individual patients who are at risk for DILI is therefore crucial. See related Research, http://genomemedicine.com/content/5/9/86.
Drug Safety R&D, Pfizer Inc., Eastern Point Rd, Groton, CT, USA.
Jiri
J
Aubrecht
Drug Safety R&D, Pfizer Inc., Eastern Point Rd, Groton, CT, USA.
Shelli J
SJ
Schomaker
Toxadvisor Toxicology Consulting, Hadlyme, CT, USA.
David E
DE
Amacher